Onconetix, INC 10-Q quarterly reports

Onconetix reports a significant revenue decline and substantial goodwill impairment in Q1 2026, while progressing with the Realbotix merger and facing ongoing going concern doubts.

Onconetix, Inc. reported a significant revenue decline and continued operating losses in its Q3 2025 filing, despite recent capital raises and debt restructuring, raising substantial doubt about its ability to continue as a going concern.

Onconetix, Inc. reports substantial losses and a going concern warning, pivoting to a merger with Ocuvex Therapeutics while grappling with significant debt and product abandonment.

Onconetix, Inc. reported a significant revenue decline and substantial operating losses for Q1 2025, raising substantial doubt about its ability to continue as a going concern, while pivoting its focus to Proclarix prostate cancer diagnostics and pursuing a potential merger with Ocuvex Therapeutics.

Onconetix's Q3 2024 report reveals a net loss of $3.8 million and significant financial challenges, including substantial doubt about its ability to continue as a going concern.

Onconetix reports a net loss of $14.3 million for Q2 2024 and faces substantial doubt about its ability to continue as a going concern due to limited cash reserves and significant debt obligations.

Onconetix reported a net loss of $11.1 million for Q1 2024 and announced a pause in ENTADFI commercialization while exploring strategic alternatives.